Economic incentives and patent protections drive development of innovative medications. Drug prices are determined by consumer demand, not production costs. Therefore, governmental regulation risks future investment in research and development.
M. Christopher Roebuck, PhD
Advertisement
Articles by M. Christopher Roebuck, PhD
Curative direct-acting antivirals for chronic hepatitis C provide a net economic benefit to Medicaid in less than 1 year. Cumulative savings to date have exceeded $15 billion.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Panel Backs 6 Peptides for Compounding
2
Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%
3
FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies
4
Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access
5